BRISBANE, Calif., June 24, 2025--āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of severe bone and connective tissue disorders, today ...

HUNTSVILLE, AL / ACCESS Newswire / June 24, 2025 / Curiteva is proud to announce FDA 510(k) clearance for the Inspire ...

Ever wondered if a meme could turn you into a millionaire? With 2025’s meme coin explosion, it’s not such a crazy question ...

Multiple myeloma causes lytic or osteolytic lesions, which are areas of damage caused by cancerous plasma cells blocking normal bone growth. While painful, they can be managed. Multiple myeloma is ...

With extensive evidence underscoring the importance of good nutrition during the early years of life, it’s important to come ...

Sensorineural hearing loss (SNHL) is the most prevalent form of permanent hearing loss, affecting over 6% of the global ...

Georgia's small businesses are navigating months of volatility and economic uncertainty due to President Donald Trump's ...

The final results of Bioretec Ltd's (Bioretec or the Company) rights issue (the Offering) show that a total of 7,658,836 new shares (the New Shares) were subscribed for in the Offering, corresponding ...

Revuforj (revumenib) is an oral, first-in-class, selective menin inhibitor that is FDA approved for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene ...